Compare TV & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TV | PHVS |
|---|---|---|
| Founded | 1969 | 2015 |
| Country | Mexico | Switzerland |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 1993 | 2021 |
| Metric | TV | PHVS |
|---|---|---|
| Price | $3.00 | $24.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $4.93 | ★ $39.44 |
| AVG Volume (30 Days) | ★ 1.4M | 563.8K |
| Earning Date | 10-23-2025 | 11-12-2025 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,246,959,081.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.55 | $11.51 |
| 52 Week High | $3.10 | $29.80 |
| Indicator | TV | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 65.67 | 47.59 |
| Support Level | $2.67 | $23.15 |
| Resistance Level | $3.07 | $29.80 |
| Average True Range (ATR) | 0.09 | 2.06 |
| MACD | 0.02 | -0.37 |
| Stochastic Oscillator | 83.54 | 15.04 |
Televisa is one of the leading telecommunication firms in Mexico. Its cable arm, Izzi, holds networks that pass 20 million Mexican homes and provide broadband service to nearly 6 million customers. The firm is also one of the largest pay-television providers in Mexico, with 4 million customers. Televisa owns Sky Mexico, the country's only satellite-TV provider, serving about 5 million customers. After merging its traditional media business into Univision, Grupo Televisa owns a 43% stake in combined entity TelevisaUnivision. Grupo Televisa spun off several smaller businesses, including magazine publishing, three of Mexico's professional soccer teams, and Azteca Stadium in February 2024, under the name Ollamani.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.